Factor XII Dependent Coagulation, Thrombin And Platelet Glycoprotein 1ba In Arterial Thrombosis And Bleeding Disorders
Funder
National Health and Medical Research Council
Funding Amount
$104,664.00
Summary
Clot formation is the key event underlying heart attacks and strokes. There is new data that Factor XII (FXII) can play an important role in clot formation-thrombosis. We aim to examine the role FXII plays in clot formation, in particular the role of FXII in thrombin generation, which is the central event of clot formation, and its interaction with platelet glycoprotein 1ba (another important molecule in thrombosis). New insights into clotting and new therapies can result from our research.
Investigating The Link Between Oxidative Stress And Biomechanical Integrin Activation In Diabetes
Funder
National Health and Medical Research Council
Funding Amount
$653,742.00
Summary
Diabetes represents a serious healthcare problem globally. A large proportion of deaths associated with diabetes can be attributed to the development of blood clots in the circulation of the heart and brain (heart attack/stroke). The blood clotting mechanism is ‘hyperactive’ in diabetes, although the reason for this is not well defined. In this proposal we will investigate a new mechanism promoting blood clots, and will investigate innovative approaches to reduce this clotting mechanism.
Autoimmune-based thrombocytopenia can be a life-threatening adverse event associated with viral load, surgery, drug therapies or the use of the anticoagulant, heparin. This grant will define mechanisms of anti-platelet antibody-dependent platelet activation and assess shedding of platelet-specific glycoprotein (GP)VI as an immediate consequence of this activation, provide a new strategy for evaluating risk of thrombosis in HIT.
Tissue factor is a central and major player in the clotting process. It exists in both active and inactive forms. The active form initiates clot formation. How it gets activated is one of the most important unanswered questions in this area of research. Our aim is to discover tissue factorÍs mechanism of activation. The outcome will provide more specific targets for therapeutic drug development for cardiovascular disease, strokes and deep venous thrombosis.